Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - yingwei+zheng
25
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Kinematic data analysis for stress detection
This technology uses movement data from laparoscopic instruments to detect stress levels in surgeons in near real-time. An AI model analyzes the data, identifying movement patterns associated with stress, and can be integrated into robotic surgical platforms for feedback and guidance. Background Laparoscopic surgery is a complex and demanding field...
Published: 10/23/2024
|
Inventor(s):
Ann Majewicz Fey
,
Yi Zheng
Keywords(s):
Category(s):
Life sciences > Diagnostic
,
Life sciences > Medical technology > TechBio (software innovation in healthcare)
Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration
Summary: The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations. Description of Technology: Inherited Retinal Degenerations (IRD), such as Leber...
Published: 12/20/2024
|
Inventor(s):
Anand Swaroop
,
Yu Holly Chen
,
Samantha Papal
,
Anupam Mondal
,
Manju Swaroop
,
Wei Zheng
,
Gregory Tawa
,
Wenwei Huang
,
Zhiji Luo
Keywords(s):
Category(s):
Application > Therapeutics
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Ear, Nose, & Throat
,
Collaboration Sought > Licensing
Fire-retardant and Spectrally Robust Melamine Formaldehyde Photonic Bulk for Efficient Daytime Radiative Cooling
INV-21082 Background: Advances in cooling technologies are essential due to rising global energy consumption driven by the need for comfortable indoor environments. Sub-ambient passive daytime radiative cooling offers a promising solution by radiating heat into space while reflecting most sunlight. However, current materials like porous polymer films...
Published: 9/10/2024
|
Inventor(s):
Yi Zheng
,
Yanpei Tian
,
Xiaojie Liu
Keywords(s):
fire retardant
,
passive radiative cooling
,
photonic bulk
,
spectrally robust
Category(s):
Technology Classifications > 2. Physical Science
Use of beclin 1 Inhibitors, including 17-hydroxy Wortmannin, to Treat TRAIL-resistant Cancer
This technology includes the use of a beclin 1 inhibitor, 17-hydroxy Wortmannin, for the treatment of TRAIL-resistant colon cancer. TRAIL (TNF-related apoptosis-inducing ligand) binds to death receptors (DR4/DR5) and activates apoptosis in cancer cells. Multiple clinical trials have focused on promoting TRAIL-induced death but have had a lack of efficacy...
Published: 10/28/2024
|
Inventor(s):
Sheng Dai
,
Wei Zheng
Keywords(s):
1
,
17-hydroxy
,
Autophagy
,
Beclin
,
CANCER
,
Cells
,
COLON
,
Increased
,
Inhibitions
,
Overcomes
,
Resistance
,
TRAIL
,
VCXXXX
,
WIXXXX
,
WKXXXX
,
Wortmannin
,
XEXXXX
Category(s):
TherapeuticArea > Oncology
,
Application > Research Materials
,
Application > Therapeutics
Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection
This invention includes the discovery and use of a group of CDK inhibitors that were found during a drug repurposing screen designed to find compounds that inhibit Zika virus caused cell death. The identified CDK inhibitors have all previously been used in clinical trials for other diseases, potentially reducing the long time course needed for new drug...
Published: 10/28/2024
|
Inventor(s):
Ruili Huang
,
Miao Xu
,
Wenwei Huang
,
Hengli Tang
,
Emily Lee
,
Cheng YiChen
,
Yi Zhou
,
Hongjun Song
,
Guo-Li Ming
,
Zhexing Wen
,
Wei Zheng
Keywords(s):
CDK
,
Infection
,
Inhibitors
,
Repurposing
,
treatment
,
VEXXXX
,
virus
,
VLXXXX
,
WIXXXX
,
WKXXXX
,
Zika
Category(s):
TherapeuticArea > Neurology
,
Application > Therapeutics
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
This technology includes the identification and use of novel ACRV1/ALK2 inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP), an autosomal-dominant rare disease that affects one person in every 1-2 million. FOP is characterized by malformation of the great (big) toes during embryonic development and by progressive heterotopic...
Published: 10/28/2024
|
Inventor(s):
Jian-kang Jiang
,
Khalida Shamim
,
Philip Sanderson
,
Wei Zheng
,
Xiuli Huang
,
Gregory Tawa
,
Asaf Alimardanov
,
Arthur Lee
,
Junfeng Huang
,
Wenwei Huang
Keywords(s):
ALK2
,
BMP
,
INHIBITING
,
Inhibitors
,
Methods
,
Novel
,
SIGNALING
,
VGXXXX
,
WIXXXX
,
WKXXXX
,
XEXXXX
Category(s):
TherapeuticArea > Endocrinology
,
Application > Therapeutics
,
Application > Research Materials
Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection
This technology includes the use of two related compounds, Emetine and Cephaeline, as a potent inhibitor of the Zika virus (ZIKV). Emetine and it's analog Cephaeline were identified in a high-throughput assay aimed at identifying anti-ZIKV compounds. Both Emetine and Cephaeline are potent inhibitors of ZIKV infection in cell culture, and Emeline is...
Published: 10/28/2024
|
Inventor(s):
Emily Lee
,
Wei Zheng
,
Miao Xu
,
Ruili Huang
,
Shu Yang
,
Wenwei Huang
,
Khalida Shamim
,
Hao Li
,
Hengli Tang
Keywords(s):
compounds
,
Emetine
,
Flavivirus
,
Infection
,
Prevention
,
treatment
,
VLXXXX
,
WIXXXX
,
WKXXXX
Category(s):
Application > Therapeutics
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
Patient-derived induced pluripotent stem cell (iPSC) lines for the study of lysosomal storage diseases (LSDs)
This technology includes the generation and use of human induced pluripotent stem cell (iPSC) lines that can be used to study and screen potential therapeutics for lysosomal storage diseases (LSDs). LSDs are a group of 50 genetic disorders caused by mutations in the genes encoding lysosomal enzymes and proteins. Although various therapeutic approaches...
Published: 10/28/2024
|
Inventor(s):
Miao Xu
,
Yu-Shan Cheng
,
Manisha Pradhan
,
Jizhong Zou
,
Jeanette Beers
,
Wei Zheng
Keywords(s):
Cell
,
COMPOUND
,
DERIVED
,
Disease
,
iPS
,
Lines
,
Lysosomal
,
Modeling
,
PATIENT
,
screening
,
Storage
,
VPXXXX
,
WIXXXX
,
XHXXXX
Category(s):
TherapeuticArea > Cardiology
,
TherapeuticArea > Infectious Disease
,
TherapeuticArea > Ophthalmology
,
TherapeuticArea > Dental
,
TherapeuticArea > Oncology
,
TherapeuticArea > Endocrinology
,
Application > Research Materials
,
ResearchProducts > Research Equipment
COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2)
The coronavirus disease 2019 (COVID-19) is caused by a novel RNA enveloped coronavirus, SARS-CoV-2 when the virus enters human airway cells via an ACE2-mediated entry process. This entry pathway is facilitated by the cell surface heparan sulfate proteoglycan (HSPG), which enhances viral attachment to the cell surface. Researchers at NIDDK and NCATS...
Published: 10/28/2024
|
Inventor(s):
Qi Zhang
,
Wei Zheng
,
Catherine Chen
,
Yihong Ye
Keywords(s):
COVID-19
,
DB4BXX
,
ENTRY
,
HEPARAN
,
option
,
Sulfate-dependent
,
Targeting
,
therapeutic
,
viral
Category(s):
Collaboration Sought > Collaboration
,
TherapeuticArea > Infectious Disease
,
Application > Therapeutics
Heterocyclic Compounds for the Treatment of Hepatitis C Virus
The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that have changed the HCV treatment paradigm. However, the...
Published: 10/28/2024
|
Inventor(s):
Zongyi Hu
,
Juan Marugan
,
Noel Southall
,
Xin Hu
,
Jingbo Xiao
,
Shanshan (Melissa) He
,
Marc Ferrer-Alegre
,
Wei Zheng
,
Kevin Frankowski
,
Frank Schoenen
,
Kelin Li
,
Tsanyang (Jake) Liang
Keywords(s):
C
,
Class
,
compounds
,
DB4BXX
,
Development
,
Hepatitis
,
Novel
,
treatment
,
VLXXXX
,
WKXXXX
,
YAXXXX
,
YBXXXX
Category(s):
Collaboration Sought > Licensing
,
Application > Therapeutics
,
TherapeuticArea > Infectious Disease
1
2
3